Works matching IS 21989788 AND DT 2024 AND VI 11 AND IP 4


Results: 19
    1
    2

    Acknowledgement to Referees.

    Published in:
    Drugs - Real World Outcomes, 2024, v. 11, n. 4, p. 553, doi. 10.1007/s40801-024-00466-7
    Publication type:
    Article
    3
    4
    5
    6

    Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.

    Published in:
    Drugs - Real World Outcomes, 2024, v. 11, n. 4, p. 573, doi. 10.1007/s40801-024-00459-6
    By:
    • Fautrel, Bruno;
    • Bouhnik, Yoram;
    • Salliot, Carine;
    • Carbonnel, Franck;
    • Fumery, Mathurin;
    • Bernardeau, Christophe;
    • Maugars, Yves;
    • Flamant, Mathurin;
    • Coury, Fabienne;
    • Braithwaite, Ben;
    • Hateb, Salima;
    • Addison, Janet
    Publication type:
    Article
    7

    Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment.

    Published in:
    Drugs - Real World Outcomes, 2024, v. 11, n. 4, p. 701, doi. 10.1007/s40801-024-00458-7
    By:
    • Fujiwara, Yudai;
    • Kuroda, Hidekatsu;
    • Abe, Tamami;
    • Kakisaka, Keisuke;
    • Nakaya, Ippeki;
    • Ito, Asami;
    • Watanabe, Takuya;
    • Yusa, Kenji;
    • Nagasawa, Tomoaki;
    • Sato, Hiroki;
    • Suzuki, Akiko;
    • Endo, Kei;
    • Yoshida, Yuichi;
    • Oikawa, Takayoshi;
    • Sawara, Kei;
    • Miyasaka, Akio;
    • Matsumoto, Takayuki
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19